Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas

BMC Biology

Volumn 9, Issue , 2011, Pages

  Chauhan, Dharminder ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRK ASSOCIATED SUBSTRATE PROTEIN; PROTEASOME;

ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; FIBROBLAST; METABOLISM; NOTE;

ANIMALS; CRK-ASSOCIATED SUBSTRATE PROTEIN; FIBROBLASTS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 80055005715     PISSN: None     EISSN: 17417007     Source Type: Journal    
DOI: 10.1186/1741-7007-9-72     Document Type: Note

References (12)

1. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009, 144:895-903. 10.1111/j.1365-2141.2008.07573.x, 19170677.
2. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005, 6:79-87.
3. Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 2007, 35:12-17.
4. Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 2005, 45:465-476. 10.1146/annurev.pharmtox.45.120403.100037, 15822185.
5. Rock K, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg A. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:761-771. 10.1016/S0092-8674(94)90462-6, 8087844.
6. Zhu K, Dunner K, McConkey DJ. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 2010, 29:451-462. 10.1038/onc.2009.343, 2809784, 19881538, 19881538.
7. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42. 10.1016/j.cell.2007.12.018, 2696814, 18191218.
8. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009, 15:5308-5316. 10.1158/1078-0432.CCR-07-5023, 2737083, 19706824.
9. Vogl D, Stadtmauer E, Bradner J, Davis L, Carroll M, Shank N, Carberry M, Swider C, Mangan P, Shelly B, et al. Combined autophagy and proteasome inhibition for multiple myeloma: preliminary results of a phase 1/2 trial of hydroxychloroquine and standard dose bortezomib for relapsed or refractory myeloma. Blood (ASH Annual Meeting Abstracts) 2008, 112:3684.
10. Zhao M, Vuori K. The docking protein p130Cas regulates cell sensitivity to proteasome inhibition. BMC Biol 2011, 9:73.
11. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P. Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 2010, 10:858-870. 10.1038/nrc2967, 21102636.
12. Holcomb M, Rufini A, Barila D, Klemke RL. Deregulation of proteasome function induces Abl-mediated cell death by uncoupling p130CAS and c-CrkII. J Biol Chem 2006, 281:2430-2440.